Nutriband Inc. Appoints Two New Directors, Updates on AVERSA Fentanyl Development
ByAinvest
Friday, Jan 30, 2026 7:02 am ET1min read
NTRB--
Nutriband Inc. has provided an update on its annual shareholder meeting, held on January 24, 2026. The company discussed key milestones and additions, including the appointment of two new directors, Alessandro Puddu and Viorica Carlig. Nutriband also highlighted developments in its AVERSA™ FENTANYL project, including strengthened collaboration with Kindeva, completion of commercial manufacturing process scale-up, and issuance of a new US patent. The company held a Type C meeting with the US FDA to obtain feedback on its Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet